OUTSOURCE
IMMUNOHISTOCHEMISTRY DIGITAL BREAST CANCER PANEL 4(Z715)
Also Known As:
IMMUNOHISTOCHEMISTRY DIGITAL BREAST CANCER PANEL 4
About This Test
ER & PR receptor assays are routinely performed on Breast carcinoma to assess responsiveness to endocrine therapy and prognosis. Her-2 expression predicts responsiveness to Herceptin therapy. Ki-67 in addition is a useful prognositc marker. Together ER, PR, Her-2 and Ki 67 help to predict prognosis and serve as surrogate IHC markers for molecular subtypes of Breast Cancer. Reporting through digital images using Visiopharm AI algorithms enhances the sensitivity of the assay.
Test Parameters (1)
- IMMUNOHISTOCHEMISTRY DIGITAL BREAST CANCER PANEL 4
Home Collection
✓ Available
Reports Available In
1 Day
Frequently Asked Questions
Outsourced test are being done from Dr. Lal Path Lab. Charges and reporting time is same as of Dr. Lal Path Labs.
Provide a copy of the Histopathology report.
The Digital Breast Cancer Panel 4 is an IHC test panel performed on breast tissue samples to evaluate specific biomarkers that provide diagnostic, prognostic, and therapeutic information for breast cancer patients. This panel uses antibodies to detect proteins expressed by tumor cells, guiding treatment decisions.
TAT Policy
The Turnaround Time (TAT) depends on the following factors:
- Registration date and time
- Type of scan or test
- Scan time or sample collection time
In uncommon circumstances, TAT may be delayed due to test complexity or reasons beyond our control. You will be informed of the estimated TAT at the time of registration.
